

EN

E-002237/2024

Answer given by Mr Várhelyi
on behalf of the European Commission
(6.1.2025)

1. The Commission is not aware of similar cases, nor did it perform an assessment of this or any similar practices in terms of a level playing field in the internal market.
2. Pricing and reimbursement measures for medicines are a Member State competence, as per Article 168 (7) of the Treaty on the Functioning of the EU¹. Financial Managed Entry Agreements (MEAs) are a common practice in Member States. This may include national agreements on the confidentiality of pharmaceutical prices. The Commission has not performed an assessment of the potential risk of market distortion due to such measures.
3. The Pharmaceutical Strategy for Europe acknowledges that fostering transparency may help Member States taking better pricing and reimbursement decisions². The Commission therefore supports the development of cooperation in the group of National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR). The Commission is also funding, through the EU4Health Programme³, relevant activities aimed at improving the transparency of pharmaceutical markets.

¹ <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A12008E168>

² COM(2020)761 final: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52020DC0761>

³ https://commission.europa.eu/funding-tenders/find-funding/eu-funding-programmes/eu4health_en